Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France.
Drug Saf. 2024 Jun;47(6):585-599. doi: 10.1007/s40264-024-01423-7. Epub 2024 May 7.
In pharmacovigilance, disproportionality analyses based on individual case safety reports are widely used to detect safety signals. Unfortunately, publishing disproportionality analyses lacks specific guidelines, often leading to incomplete and ambiguous reporting, and carries the risk of incorrect conclusions when data are not placed in the correct context. The REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV) statement was developed to address this issue by promoting transparent and comprehensive reporting of disproportionality studies. While the statement paper explains in greater detail the procedure followed to develop these guidelines, with this explanation paper we present the 14 items retained for READUS-PV guidelines, together with an in-depth explanation of their rationale and bullet points to illustrate their practical implementation. Our primary objective is to foster the adoption of the READUS-PV guidelines among authors, editors, peer reviewers, and readers of disproportionality analyses. Enhancing transparency, completeness, and accuracy of reporting, as well as proper interpretation of their results, READUS-PV guidelines will ultimately facilitate evidence-based decision making in pharmacovigilance.
在药物警戒中,基于个体病例安全报告的比例失调分析被广泛用于检测安全信号。不幸的是,发表比例失调分析缺乏具体的指导方针,往往导致报告不完整和模糊,并在数据没有置于正确的背景下时存在错误结论的风险。《使用个体病例安全报告进行药物警戒中药物安全性信号检测的比例失调分析报告(READUS-PV)声明》的制定是为了解决这个问题,通过促进比例失调研究的透明和全面报告。虽然声明文件更详细地解释了制定这些指南所遵循的程序,但通过这份解释文件,我们提出了 READUS-PV 指南保留的 14 项内容,以及对其基本原理和要点的深入解释,以说明其实际实施情况。我们的主要目标是促进作者、编辑、同行评审员和比例失调分析读者采用 READUS-PV 指南。提高报告的透明度、完整性和准确性,以及正确解释其结果,READUS-PV 指南最终将有助于药物警戒中的循证决策。